If patients are randomized to Arm A, they will be administered pembrolizumab (200 mg), by IV, every three weeks. Pembrolizumab can be administered up to two years, if disease does not progress or have unacceptable toxicity. However, if the disease progresses the patient may continue on the study if they are clinically stable or clinically improved.